Nisa Investment Advisors LLC Sells 400 Shares of Glaukos Co. (NYSE:GKOS)

Nisa Investment Advisors LLC decreased its position in Glaukos Co. (NYSE:GKOS) by 9.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,805 shares of the medical instruments supplier’s stock after selling 400 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Glaukos were worth $323,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Altshuler Shaham Ltd bought a new position in Glaukos in the first quarter valued at about $38,000. Eaton Vance Management bought a new position in Glaukos in the first quarter valued at about $40,000. Benjamin F. Edwards & Company Inc. bought a new position in Glaukos in the first quarter valued at about $50,000. Marshall Wace North America L.P. bought a new position in Glaukos in the first quarter valued at about $55,000. Finally, Fifth Third Bancorp lifted its holdings in Glaukos by 566.7% in the first quarter. Fifth Third Bancorp now owns 800 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 680 shares during the period.

GKOS has been the topic of a number of recent research reports. Stephens lowered their target price on Glaukos from $70.00 to $60.00 and set an “equal weight” rating on the stock in a report on Friday, August 6th. Wells Fargo & Company downgraded Glaukos from an “equal weight” rating to an “underweight” rating and set a $41.00 price objective on the stock. in a research note on Tuesday, July 20th. William Blair downgraded Glaukos from an “outperform” rating to a “market perform” rating and set a $34.00 price objective on the stock. in a research note on Wednesday, July 14th. TheStreet downgraded Glaukos from a “c-” rating to a “d+” rating in a research note on Wednesday, May 26th. Finally, Piper Sandler decreased their price objective on Glaukos from $80.00 to $45.00 and set a “neutral” rating on the stock in a research note on Friday, August 6th. Two analysts have rated the stock with a sell rating and seven have given a hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $59.00.

NYSE:GKOS opened at $50.02 on Wednesday. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 0.12. Glaukos Co. has a 12-month low of $43.66 and a 12-month high of $99.00. The stock has a 50-day moving average price of $54.92 and a 200 day moving average price of $73.30. The stock has a market capitalization of $2.33 billion, a P/E ratio of -37.61 and a beta of 1.67.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, August 5th. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.13. Glaukos had a negative return on equity of 3.13% and a negative net margin of 21.24%. The firm had revenue of $78.09 million during the quarter, compared to analysts’ expectations of $71.00 million. On average, research analysts predict that Glaukos Co. will post -0.85 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.

Recommended Story: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.